FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2266301144> ?p ?o ?g. }

• W2266301144 abstract "15179 Background: To date, gemcitabine (GEM) remains the cornerstone of chemotherapy (CHT) for APC. According to GERCOR and GISCAD phase III trials the combination of GEM and oxaliplatin (GEMOX) has proven superior to GEM alone in terms of response rate (RR), time to progression (TTP) and clinical benefit rate (CBR). Methods: We conducted a retrospective analysis on 19 patients (pts) affected with histologically-confirmed APC, in order to determine the impact of GEMOX as first-line chemotherapy in terms of objective responses (OR) and TTP, using the Kaplan-Meier method. Among the 19 pts considered there were 15 males and 4 females (median age at diagnosis of 60.84 yrs; ECOG 0–2). The staging, according to AJCC criteria, was: IIB in 1 case, III in 5 cases and IV in the 13 remaning cases. The only metastatic site was the liver (in 13/19 pts). Ten of the 19 pts underwent surgical treatment prior to CHT: 2 radically resected (R0) subsequently treated with GEMOX after recurrence, 4 with positive margins (R1) and 4 surgically palliated. All pts received GEM 1000 mg/m2/d1 + oxaliplatin 100 mg/m2/d2 every 2 weeks. The median number of cycles was 5.89. Results: Among the 19 pts, 3 had a partial response (PR, 15.69%), 6 had stable disease (SD, 31.57%); no complete response was observed and 10 pts had progressive disease (PD, 52.63%). The overall disease control rate (DCR: PR + SD) was 47.37% while the OR were 15.69%. The median survival observed was 9.03 months (95% C.I. 5.15–12.91) and the median TTP was 6.13 months (95% C.I. 2.81–9.46). The main toxicities were: leucopenia, piastrinopenia, diarrhoea, nausea, fever and peripheral neuropathy; 3 pts discontinued the treatment due to grade 3–4 neurotoxicity. Conclusions: In our experience GEMOX gives an improved control of APC in terms of OR and TTP, with acceptable toxicity. The OS is in accordance to literature as well as the other data. No significant financial relationships to disclose." @default.
• W2266301144 created "2016-06-24" @default.
• W2266301144 creator A5002306207 @default.
• W2266301144 creator A5011842580 @default.
• W2266301144 creator A5017497738 @default.
• W2266301144 creator A5025941399 @default.
• W2266301144 creator A5035051606 @default.
• W2266301144 creator A5065743678 @default.
• W2266301144 creator A5067159913 @default.
• W2266301144 creator A5068055005 @default.
• W2266301144 creator A5082731074 @default.
• W2266301144 creator A5085632200 @default.
• W2266301144 date "2007-06-20" @default.
• W2266301144 modified "2023-09-25" @default.
• W2266301144 title "GEMOX as first-line chemotherapy in advanced pancreatic cancer (APC): A monoinstitutional experience" @default.
• W2266301144 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15179" @default.
• W2266301144 hasPublicationYear "2007" @default.
• W2266301144 type Work @default.
• W2266301144 sameAs 2266301144 @default.
• W2266301144 citedByCount "0" @default.
• W2266301144 crossrefType "journal-article" @default.
• W2266301144 hasAuthorship W2266301144A5002306207 @default.
• W2266301144 hasAuthorship W2266301144A5011842580 @default.
• W2266301144 hasAuthorship W2266301144A5017497738 @default.
• W2266301144 hasAuthorship W2266301144A5025941399 @default.
• W2266301144 hasAuthorship W2266301144A5035051606 @default.
• W2266301144 hasAuthorship W2266301144A5065743678 @default.
• W2266301144 hasAuthorship W2266301144A5067159913 @default.
• W2266301144 hasAuthorship W2266301144A5068055005 @default.
• W2266301144 hasAuthorship W2266301144A5082731074 @default.
• W2266301144 hasAuthorship W2266301144A5085632200 @default.
• W2266301144 hasConcept C121608353 @default.
• W2266301144 hasConcept C126322002 @default.
• W2266301144 hasConcept C141071460 @default.
• W2266301144 hasConcept C143998085 @default.
• W2266301144 hasConcept C2776694085 @default.
• W2266301144 hasConcept C2780210213 @default.
• W2266301144 hasConcept C2780258809 @default.
• W2266301144 hasConcept C2780962732 @default.
• W2266301144 hasConcept C526805850 @default.
• W2266301144 hasConcept C71924100 @default.
• W2266301144 hasConceptScore W2266301144C121608353 @default.
• W2266301144 hasConceptScore W2266301144C126322002 @default.
• W2266301144 hasConceptScore W2266301144C141071460 @default.
• W2266301144 hasConceptScore W2266301144C143998085 @default.
• W2266301144 hasConceptScore W2266301144C2776694085 @default.
• W2266301144 hasConceptScore W2266301144C2780210213 @default.
• W2266301144 hasConceptScore W2266301144C2780258809 @default.
• W2266301144 hasConceptScore W2266301144C2780962732 @default.
• W2266301144 hasConceptScore W2266301144C526805850 @default.
• W2266301144 hasConceptScore W2266301144C71924100 @default.
• W2266301144 hasLocation W22663011441 @default.
• W2266301144 hasOpenAccess W2266301144 @default.
• W2266301144 hasPrimaryLocation W22663011441 @default.
• W2266301144 hasRelatedWork W1523425138 @default.
• W2266301144 hasRelatedWork W2007621813 @default.
• W2266301144 hasRelatedWork W2054312082 @default.
• W2266301144 hasRelatedWork W2093930824 @default.
• W2266301144 hasRelatedWork W2107139876 @default.
• W2266301144 hasRelatedWork W2182918865 @default.
• W2266301144 hasRelatedWork W2349340765 @default.
• W2266301144 hasRelatedWork W2376347278 @default.
• W2266301144 hasRelatedWork W2410090482 @default.
• W2266301144 hasRelatedWork W2599910524 @default.
• W2266301144 isParatext "false" @default.
• W2266301144 isRetracted "false" @default.
• W2266301144 magId "2266301144" @default.
• W2266301144 workType "article" @default.